+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Impact of beta1-adrenergic receptor polymorphisms on susceptibility to heart failure, arrhythmogenesis, prognosis, and response to beta-blocker therapy



Impact of beta1-adrenergic receptor polymorphisms on susceptibility to heart failure, arrhythmogenesis, prognosis, and response to beta-blocker therapy



American Journal of Cardiology 102(6): 726-732



Beta1-adrenergic receptor polymorphisms have been implicated with inconsistent results in the pathogenesis, clinical presentation, and prognosis of patients with heart failure (HF). The impact of 2 functional polymorphisms (beta1-Arg389Gly and beta1-Ser49Gly) on HF susceptibility, arrhythmogenesis, and prognosis was evaluated in Brazilian outpatients. Genotyping at codons 389 and 49 was performed using polymerase chain reaction with restriction fragment length polymorphism analysis in 201 outpatients with systolic HF and 141 apparently healthy controls. Enrolled patients were followed up at the HF clinic, and vital status was evaluated using electronic hospital records, telephone contact, and a local death certificate database. Allele frequencies were similar between patients with HF and controls, with neither polymorphism related to HF susceptibility. The beta1-389Gly homozygotes had significantly less nonsustained ventricular tachycardia on Holter monitoring (17% vs 48% for Arg/Arg patients; p = 0.015) and improved HF-related survival, with no events after a median follow-up of 40 months (log-rank statistics = 0.025). The negative impact of beta1-389Arg allele on HF-related survival was substantially reduced using high-dose beta-blocker therapy (80% survival for high-dose vs 42% for low-dose beta blockers or nonusers; log-rank statistics = 0.0003). The beta1-Ser49Gly polymorphism was not associated with nonsustained ventricular tachycardia or HF prognosis. In conclusion, beta1-Arg389Gly and beta1-Ser49Gly polymorphisms had no influence on HF susceptibility. However, the Gly389 allele was associated with a lower prevalence of ventricular arrhythmias and better HF-related survival. A pharmacogenetic interaction is suggested because beta blockers were more effective in beta1-389Arg allele carriers.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 053712947

Download citation: RISBibTeXText

PMID: 18773997

DOI: 10.1016/j.amjcard.2008.04.070


Related references

β1 adrenergic receptor polymorphisms and heart failure: a meta-analysis on susceptibility, response to β-blocker therapy and prognosis. Plos One 7(7): E37659, 2013

Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure. Pharmacogenetics and Genomics 17(4): 277-282, 2007

A pilot study on the role of autoantibody targeting the beta1-adrenergic receptor in the response to beta-blocker therapy for congestive heart failure. Journal of Cardiac Failure 15(3): 224-232, 2009

Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenetics and Genomics 15(4): 227-234, 2005

β-adrenergic receptor polymorphisms in susceptibility, response to treatment and prognosis in heart failure: implication of ethnicity. Molecular Medicine Reports 7(1): 259-265, 2014

Impact of beta-2 Thr164Ile and combined beta-adrenergic receptor polymorphisms on prognosis in a cohort of heart failure outpatients. Brazilian Journal of Medical and Biological Research 43(6): 565-571, 2011

Selective upregulation of the beta1-adrenergic receptor, dephosphorylation of cardiac troponin I and influence of beta-blocker therapy in patients suffering from terminal heart failure and supported by ventricular assist devices. Journal of Heart & Lung Transplantation 23(2S): S53, 2004

BETA1 and BETA2 adrenergic receptor polymorphisms and heart failure survival Interaction with beta blockade. Circulation 106(19 Suppl.): II-611, November 5, 2002

Polymorphisms of the beta-2 adrenergic receptors may influence the effects of beta-blocker therapy in the patients with chronic heart failure. European Heart Journal 24(Abstract Suppl.): 711, August-September, 2003

Beta-adrenergic receptor polymorphisms and antihypertensive response to beta-blocker therapy. Clinical Pharmacology & Therapeutics 71(2): P2, 2002

Differential regulation of beta1- and beta2-adrenergic receptor proteins, and beta1-adrenergic receptor protein and mRNA expression in response to beta-agonist exposure in isolated human heart preparations. Circulation 98(17 SUPPL ): I491, Oct 27, 1998

A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proceedings of the National Academy of Sciences of the United States of America 103(30): 11288-11293, 2006

Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenetics and Genomics 15(3): 137-142, 2005

Relationship between beta-1 adrenergic receptor polymorphisms and the response to beta-blockers in patients with heart failure. Circulation 104(17 Suppl.): II 661-II 662, October 23, 2001

Consideration of beta-1 adrenergic receptor polymorphisms along with traditional risk factors as predictors of prognosis in patients with heart failure. Clinical Pharmacology & Therapeutics 75(2): P55, 2004